Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats

Table 3 Disease activity score rate

Groups	Days
	1	2	3	4	5	6	7	8	9	10	11
HC	0	0	0	0	0	0	0	0	0	0	0
DC	0	0.67 ± 1.15	0.87 ± 1.50	2.53 ± 0.50	2.63 ± 0.65	2.63 ± 0.65	2.97 ± 0.85	3.12 ± 1.80	3.22 ± 1.70	3.23 ± 2.00	3.30 ± 2.0
MMF	0	0.33 ± 0.58	0.67 ± 1.15	1.07 ± 1.29	1.53 ± 0.50	2.53 ± 0.0	2.10 ± 0.85	1.07 ± 0.51	0.73 ± 0.81	0.23 ± 0.68	0c
MPA	0	0.43 ± 0.75	0.67 ± 1.15	2.50 ± 0.17	2.63 ± 0.35	2.63 ± 0.35	2.33 ± 0.58	1.97 ± 0.65	1.63 ± 0.91	0.97 ± 0.85	0.77 ± 0.68c
MGLS	0	0.33 ± 0.58	0.33 ± 0.58	1.77 ± 0.40	1.97 ± 0.65	2.53 ± 1.08	1.73 ± 1.03	1.06 ± 0.50	0.63 ± 0.65	0.33 ± 0.17	0c
MGAS	0	0.33 ± 0.58	0.43 ± 0.75	1.53 ± 0.81	2.10 ± 0.17	2.33 ± 0.58	1.73 ± 1.03	0.93 ± 0.58	0.73 ± 0.81	0.50 ± 0.35	0.30 ± 0.1c
GL	0	0.33 ± 0.58	0.67 ± 1.15	2.1 ± 0.85	2.3 ± 0.89	2.53 ± 0.50	2.1 ± 0.85	1.73 ± 0.75	1.40 ± 0.17	1.20 ± 0.40	1.02 ± 0.2b
GA	0	0.43 ± 0.75	0.67 ± 1.15	2.17 ± 0.75	2.53 ± 0.50	2.53 ± 0.52	2.33 ± 0.58	2.10 ± 0.85	1.50 ± 1.01	1.39 ± 1.00	1.30 ± 0.4b
GL + MPA	0	0.33 ± 0.58	0.33 ± 0.58	1.83 ± 0.68	2.17 ± 0.75	2.17 ± 0.75	1.87 ± 0.51	1.30 ± 0.70	0.93 ± 0.58	0.53 ± 0.50	0.40 ± 0.35c
GA + MPA	0	0.33 ± 0.58	0.667 ± 1.15	1.97 ± 0.65	1.97 ± 0.654	2.3 ± 0.89	1.77 ± 0.51	1.17 ± 0.51	0.73 ± 0.23	0.53 ± 0.50	0.40 ± 0.35c

Average of six readings; two-way ANOVA followed by Bonferroni’s Test, statistical significance considered at

^cP < 0.001 Disease control. HC: Healthy control; DC: Disease control; MMF: Mycophenolate mofetil; MPA: Mycophenolic acid; MGLS: Prodrug of MPA and D-glucosamine; MGAS: Prodrug of MPA and D-galactosamine; GL: D-glucosamine; GA: D-galactosamine; GL+MPA: Physical mixture of D-glucosamine and MPA; GA + MPA oral: Physical mixture of D-galactosamine and MPA.